- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
- Interventions
- F-18 AV 1451, C-11 PiB
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Condition Directory
Mild Cognitive Impairment clinical trials
Directory of U.S. ClinicalTrials.gov public records for Mild Cognitive Impairment. Browse Mild Cognitive Impairment recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 24, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
148
Shown on this page
12
Current sort
Recently updated
Condition scope
Mild Cognitive Impairment
Additional filters apply within this condition.
How Mild Cognitive Impairment studies are organized in the registry
MCI is the registry’s main gateway term for early-stage memory and Alzheimer’s-prevention research; “amnestic MCI” labels the memory-specific subset. The portfolio includes a high share of observational cohort studies from memory clinics, so the study-type filter cleanly separates those from interventional trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 1–12 of 148 matching trials for Mild Cognitive Impairment.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- AAV2-BDNF Gene Therapy, AAV2-BDNF Gene Therapy
- Genetic · Biological
- Lead sponsor
- Mark Tuszynski
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • Columbus, Ohio
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- LEADing Dementia End-of-Life Planning Conversations
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Alzheimers Disease
- Interventions
- Trontinemab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Imperial, California • Long Beach, California + 29 more
- Conditions
- Alzheimers Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 13,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 45 more
- Conditions
- Alzheimers Disease
- Interventions
- Trontinemab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Interventions
- repetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation rTMS
- Device · Other
- Lead sponsor
- Chi-Ying (Roy) Lin
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dementia, Alzheimer Disease, Mild Cognitive Impairment, Worried Well
- Interventions
- electronic self administered gerocognitive examination (eSAGE)
- Diagnostic Test
- Lead sponsor
- Douglas Scharre
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 1,486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Alzheimer Disease
- Interventions
- LY3372689, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 327 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Fresno, California • Irvine, California + 30 more
About this Mild Cognitive Impairment clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Mild Cognitive Impairment as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Mild Cognitive Impairment.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Mild Cognitive Impairment.